文献速递哮喘

低剂量口服糖皮质激素与哮喘患者发病率和死亡率增加相关

Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality.
PubMed 文献 · Eur Respir J · 2022-09-15

该研究基于丹麦全国登记数据(1999-2018年),纳入18-45岁哮喘用药者,采用倾向评分匹配(1:4)比较口服糖皮质激素(OCS)使用者和非使用者。结果显示,OCS使用者即使累积剂量≤500 mg(泼尼松龙等效),所有结局风险均增加,且存在明显剂量反应关系。研究提示优化哮喘控制、减少OCS使用至关重要。

要点

  • 低累积剂量OCS(≤500 mg泼尼松龙等效)即与哮喘患者多种合并症风险增加相关。
  • OCS使用者哮喘特异性死亡率较低,但全因死亡率和非计划就诊率随暴露增加而升高。
  • 临床应优先采用有效策略优化哮喘控制,减少OCS使用。

核心结论

  • 在哮喘管理中,即使低累积暴露的OCS使用也与合并症、死亡率和非计划医院就诊风险增加相关。

研究设计与样本

  • 基于丹麦全国登记的前瞻性开放队列研究,纳入1999-2018年18-45岁哮喘用药者。
  • 发生OCS使用的新使用者按倾向评分1:4匹配非使用者(有放回匹配),OCS使用者n=30 352,非使用者n=121 408。
  • 采用Cox回归分析OCS使用与 incident 合并症之间的关联。

主要发现

  • OCS使用者相比非使用者,所有结局风险均增加,且从累积剂量≤500 mg(泼尼松龙等效)开始呈现明显剂量反应关系。
  • 风险比范围从骨折的1.24(95% CI 1.18-1.30)到肾上腺功能不全的8.53(95% CI 3.97-18.33)。
  • 抑郁/焦虑的发病率差最高,为每1000人年4.3(95% CI 3.6-5.0)。
  • OCS使用者和非使用者的哮喘特异性死亡率分别为每1000人年0.15(95% CI 0.11-0.20)和0.04(95% CI 0.02-0.06)。
  • 死亡率和非计划医院就诊率随OCS暴露增加而升高。

临床怎么用

  • 临床应重视哮喘患者OCS的累积暴露,即使低剂量也可能增加合并症和死亡风险。
  • 采取有效策略优化哮喘控制,减少OCS使用是哮喘管理的关键。

局限性

  • 研究为观察性设计,结果解读需考虑其观察性本质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term oral corticosteroid (OCS) treatment for severe asthma is known to cause significant adverse effects, but knowledge on effects of lower exposures in general asthma populations is limited. We aimed to explore this in a nationwide Danish asthma population. METHODS: Users of asthma medication aged 18-45 years were identified in the Danish nationwide registers during 1999-2018 and followed prospectively in an open-cohort design. Incident OCS users were matched 1:4 to nonusers by propensity scores with replacement. Associations between OCS use and incident comorbidities were examined by Cox regression. Mortality rates, causes of death and rates of unscheduled hospital visits were assessed. RESULTS: OCS users (n=30 352) had, compared with nonusers (n=121 408), an increased risk of all outcomes with evident dose-response relationships starting at cumulative doses of ≤500 mg (prednisolone-equivalent). Hazard ratios ranged from 1.24 (95% CI 1.18-1.30) for fractures to 8.53 (95% CI 3.97-18.33) for adrenal insufficiency. Depression/anxiety had the highest incidence rate difference at 4.3 (95% CI 3.6-5.0) per 1000 person-years. Asthma-specific mortality rates were generally low at 0.15 (95% CI 0.11-0.20) and 0.04 (95% CI 0.02-0.06) per 1000 person-years for OCS users and nonusers, respectively. Mortality rates and unscheduled hospital visits increased with increasing OCS exposure. CONCLUSION: The study findings should be interpreted with their observational nature in mind. However, we found that even at low cumulative exposure, OCS use in asthma management was associated with increased risk of comorbidities, mortality and unscheduled hospital visits. Effective strategies for optimising asthma control and reducing OCS use are pivotal in asthma management.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Skov IR, Madsen H, Henriksen DP, et al. Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality. Eur Respir J. 2022. PMID: 35144997. doi:10.1183/13993003.03054-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。